EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Orally deliverable biomimetic nucleic acid therapies for targeted treatment of atherosclerosis

Chenwen Li, Yidan Chen, Yuan Li, Huan Liu, Shengqian Yang, Yongyao Lin, Yuantong Qi, Songling Han, Yin Dou, Gaoxing Luo, Yingxue Hao, Jianxiang Zhang

Acta Pharmaceutica Sinica B · 2025-11 · 15 (11) · 6052-6069

DOI: 10.1016/j.apsb.2025.07.039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-11. Verfasst von Chenwen Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, Third Military Medical University (Army Medical University), Chongqing 400038, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation Project of Chongqing, Natural Science Foundation of Chongqing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accumulating evidence has demonstrated that nucleic acid-based therapies are promising for atherosclerosis. However, nearly all nucleic acid delivery systems developed for atherosclerosis necessitate injection, which results in rapid elimination and poor patient compliance. Consequently, oral delivery strategies capable of targeting atherosclerotic plaques are imperative for nucleic acid therapeutics. Herein we report the development of yeast-derived capsules (YCs) packaging an antisense oligonucleotide (AM33) targeting microRNA-33 (miR-33) for the oral treatment of atherosclerosis. YCs provide stability for AM33, preventing its premature release in the gastrointestinal tract. AM33-containing YCs, defined as YAM33, showed high transfection in macrophages, thus promoting cholesterol efflux and inhibiting foam cell formation by regulating the target genes/proteins of miR-33. Orally delivered YAM33 effectively accumulated within atherosclerotic plaques in ApoE -/- mice, primarily by transepithelial absorption via M cells in Peyer's patches and subsequent translocation via macrophages through the lymphatic system. Inhibition of miR-33 by oral YAM33 significantly delayed the progression of atherosclerosis. Moreover, oral treatment with YCs co-delivering AM33 and atorvastatin afforded significantly enhanced anti-atherosclerotic effects. Our findings suggest that yeast-based microcapsules represent an effective carrier for oral delivery of nucleic acids, either alone or in combination with existing drugs, offering a promising approach for precision therapy of atherosclerotic diseases.

Schlagwörter

Stichwörter der Autor:innen

AtherosclerosisCholesterol effluxLymphatic transportMicrocapsuleNucleic acidOral deliveryTargeted therapymicroRNA-33

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmacy, Third Military Medical University (Army Medical University), Chongqing 400038, China.
  • Yu-Yue Pathology Scientific Research Center, Chongqing 400039, China.
  • Department of Neurology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
  • Department of Vascular Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
  • State Key Laboratory of Trauma and Chemical Poisoning, Third Military Medical University (Army Medical University), Chongqing 400038, China.

Förderung

  • China Postdoctoral Science Foundation
  • Natural Science Foundation Project of Chongqing
  • Natural Science Foundation of Chongqing Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Li, C., Chen, Y., Li, Y., Liu, H., Yang, S., Lin, Y., Qi, Y., Han, S., Dou, Y., Luo, G., Hao, Y., & Zhang, J. (2025). Orally deliverable biomimetic nucleic acid therapies for targeted treatment of atherosclerosis. Acta Pharmaceutica Sinica B, 15(11), 6052-6069. https://doi.org/10.1016/j.apsb.2025.07.039

Vancouver

Li C, Chen Y, Li Y, Liu H, Yang S, Lin Y, et al. Orally deliverable biomimetic nucleic acid therapies for targeted treatment of atherosclerosis. Acta Pharmaceutica Sinica B. 2025;15(11):6052-6069. doi:10.1016/j.apsb.2025.07.039

BibTeX
@article{Li2025,
  author = {Li, Chenwen and Chen, Yidan and Li, Yuan and Liu, Huan and Yang, Shengqian and Lin, Yongyao and Qi, Yuantong and Han, Songling and Dou, Yin and Luo, Gaoxing and Hao, Yingxue and Zhang, Jianxiang},
  title = {Orally deliverable biomimetic nucleic acid therapies for targeted treatment of atherosclerosis},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {11},
  pages = {6052--6069},
  doi = {10.1016/j.apsb.2025.07.039}
}
Kostenlos starten →